Cohort study evaluates p53 status and its impact on survival outcomes in women with stage I endometrial cancer, implying clinical relevance.
In Australia women have a 2.3% risk of endometrial cancer (EC). p53 mutation (p53m), often associated with poorer prognosis, guides adjuvant therapy following TCGA and FIGO 2023 updates. This study evaluated uptake of molecular testing and survival outcomes in stage 1 EC based on p53 status.
No takes yet. Share an insight, caveat, or question.
Scott et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: